BioCentury
ARTICLE | Clinical News

Ninlaro ixazomib regulatory update

September 26, 2016 7:00 AM UTC

EMA’s CHMP recommended conditional approval of Ninlaro ixazomib from Takeda in combination with Revlimid lenalidomide and dexamethasone to treat relapsed or refractory multiple myeloma (MM) in patien...